Neuphoria Therapeutics Inc.

Final Neuphoria Therapeutics Inc. Annual Report Summary for Investors

---

Key Risks to Consider

1. Clinical Trial Risks

• High failure rate in late-stage trials: Early success (e.g., Phase 2 PTSD/anxiety trials) doesn’t guarantee Phase 3 success. Example: A safety study in Australia with 32 healthy volunteers showed promise, but larger trials could reveal safety issues or inefficacy.
• Tiny studies = big uncertainties: A recent food-effect trial used only 4 participants – results from such small groups may not predict real-world outcomes.
• Patient recruitment challenges: Strict eligibility criteria (e.g., severe PTSD cases only) and competition for participants could delay trials.
• Cost overruns: Trials may exceed budgets, draining cash reserves.

2. Regulatory Hurdles

• FDA rejections or restrictions: The FDA already denied their “Breakthrough Therapy” request for BNC210 in 2025. Even if approved, the drug could face narrow usage labels (e.g., only for mild Alzheimer’s) or costly post-approval studies.
• Fast Track ≠ guaranteed approval: Fast Track status helps, but the FDA can still demand more data.

3. Profitability Challenges

• Royalty uncertainty: Their deal with Merck pays royalties between 2-12% on BNC210 sales, but only if sales hit specific targets. Underperformance = minimal payouts.
• Price controls: Government efforts to cap drug prices or investigate pricing algorithms (e.g., FTC/DOJ probes) could squeeze margins.
• Small company, big competitors: As a “non-accelerated filer” (market value <$75M), Neuphoria lacks the financial muscle of rivals like Pfizer to fund trials or absorb setbacks.

4. Manufacturing & Partnerships

• Third-party failures: Their cancer drug BNC101 (partnered with Carina Biotech) risks losing up to $75.8M in milestone payments if trials fail.
• Production risks: Scaling up manufacturing (e.g., the suspension formulation tested in Australia) could lead to recalls or delays if partners make errors.

5. Global Risks

• Patent copycats: Weak IP laws in some countries may allow generic competitors to steal formulas.
• Currency swings: A drop in the Australian dollar (where they get R&D rebates) could reduce the value of overseas earnings.

6. Leadership & Talent

• Key person risk: Losing CEO Spyros Papapetropoulos or clinical lead Liz Doolin could disrupt progress.

---

The Bottom Line for Investors

High Risk, High Reward?
Neuphoria is a speculative bet. Their success hinges on:

1. Clinical trial wins (especially Phase 3 for PTSD/anxiety drug BNC210).
2. FDA approvals without heavy restrictions.
3. Partnerships to fund early-stage projects (e.g., schizophrenia drugs).

Red Flags to Watch:

• Tiny trial sizes raising reliability questions.
• Reliance on Merck royalties that may never materialize.
• Competition from deep-pocketed rivals.

Transparency Note: The company provided limited details on year-over-year financial performance or revenue growth, which makes assessing their trajectory challenging.

Investment Verdict:

• Avoid if you’re risk-averse or prefer stable returns.
• Consider only as a high-risk portion of a diversified portfolio, understanding that clinical failures or FDA rejections could lead to significant losses.

Always consult a financial advisor before investing in biotech stocks.